These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 3489069)

  • 41. [MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and parkinsonism].
    Gao XM; Ku BS
    Sheng Li Ke Xue Jin Zhan; 1989 Apr; 20(2):161-3. PubMed ID: 2686017
    [No Abstract]   [Full Text] [Related]  

  • 42. Parkinson's disease. A review.
    Voiculescu V
    Rom J Neurol Psychiatry; 1991; 29(3-4):103-10. PubMed ID: 1820097
    [No Abstract]   [Full Text] [Related]  

  • 43. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
    Chiueh CC; Markey SP; Burns RS; Johannessen JN; Jacobowitz DM; Kopin IJ
    Psychopharmacol Bull; 1984; 20(3):548-53. PubMed ID: 6332333
    [No Abstract]   [Full Text] [Related]  

  • 44. Street-drug contaminant causing parkinsonism.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1984 Jun; 33(24):351-2. PubMed ID: 6427583
    [No Abstract]   [Full Text] [Related]  

  • 45. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Street drugs yield primate Parkinson's model.
    Blume E
    JAMA; 1983 Jul; 250(1):13-4. PubMed ID: 6602228
    [No Abstract]   [Full Text] [Related]  

  • 47. Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis.
    Wright JM; Wall RA; Perry TL; Paty DW
    N Engl J Med; 1984 Feb; 310(5):325. PubMed ID: 6606784
    [No Abstract]   [Full Text] [Related]  

  • 48. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parkinson's disease, 1984.
    Lancet; 1984 Apr; 1(8381):829-30. PubMed ID: 6143142
    [No Abstract]   [Full Text] [Related]  

  • 52. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T
    Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MPTP: insights into the etiology of Parkinson's disease.
    Langston JW
    Eur Neurol; 1987; 26 Suppl 1():2-10. PubMed ID: 3556187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etiology of Parkinson's disease: current concepts.
    Duvoisin RC
    Clin Neuropharmacol; 1986; 9 Suppl 1():S3-21. PubMed ID: 2423234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Parkinson's disease: an environmental cause?
    Lewin R
    Science; 1985 Jul; 229(4710):257-8. PubMed ID: 3925554
    [No Abstract]   [Full Text] [Related]  

  • 59. Fetal-tissue transplants in Parkinson's disease.
    Fahn S
    N Engl J Med; 1992 Nov; 327(22):1589-90. PubMed ID: 1435887
    [No Abstract]   [Full Text] [Related]  

  • 60. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M; Rojas P; Kravzov J; Rios C
    Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.